PW2101 is a beta blocker intended for the treatment of hypertension and angina. The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due... The development of PW2101 has since been discontinued.
- Mechanism
- Curator reviewed
Beta blockers block the action of endogenous catecholamines (epinephrine (adrenaline) and norepinephrine (noradrenaline) in particular), on β-adrenergic receptors, part of the sympathetic nervous system which mediates the fight or flight response. Beta blockers inhibit these normal epinephrine-mediated sympathetic actions, but have minimal effect on resting subjects. The antihypertensive mechanism appears to involve: reduction in cardiac output (due to negative chronotropic and inotropic effects), reduction in renin release from the kidneys, and a central nervous system effect to reduce sympathetic activity (for those beta-blockers that do cross the blood-brain barrier, e.g. Propranolol). Antianginal effects result from negative chronotropic and inotropic effects, which decrease cardiac workload and oxygen demand.
- Primary indication
- Investigated for use/treatment in hypertension and angina.Curator reviewed
- Code names
- PW2101
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with PW2101, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account